Naseem Zojwalla Sells 70,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Naseem Zojwalla sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $28.20, for a total transaction of $1,974,000.00. Following the completion of the transaction, the insider owned 103,997 shares in the company, valued at approximately $2,932,715.40. This trade represents a 40.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Naseem Zojwalla also recently made the following trade(s):

• On Tuesday, December 23rd, Naseem Zojwalla sold 99,509 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $27.66, for a total transaction of $2,752,418.94.
• On Monday, December 22nd, Naseem Zojwalla sold 100,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $28.04, for a total transaction of $2,804,000.00.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $27.34 on Thursday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a market cap of $1.88 billion, a P/E ratio of -14.62 and a beta of 1.87. The firm’s fifty day moving average price is $18.92 and its 200-day moving average price is $10.68.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). On average, equities research analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha reiterates a “Strong Buy” on Olema driven by initiation of the OPERA‑02 pivotal trial and promising combo data (palazestrant + KISQALI), highlighting OPERA‑01 readout in 2H‑2026 and OPERA‑02 topline in 2028 as key value catalysts. Seeking Alpha – Strong Buy on OPERA‑02
• Positive Sentiment: Several sell‑side firms have raised targets and reiterated buys (Goldman, Citi, JPMorgan, UBS), lifting the consensus price target (~$40.50 average), which supports upside if clinical milestones land.
• Neutral Sentiment: Reported short interest data shows effectively zero shares short and a 0.0 days‑to‑cover figure, indicating short sellers are not currently positioned to amplify moves (data appears to show no measurable short interest for December).
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at ~$29.73 (≈$7.87M), a large director‑level disposal that can raise governance/lockup concern and pressure the stock. SEC Form 4 – Clark sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla executed multiple large sales (100,000; 70,000; 99,509 shares across Dec. 19–23), reducing his stake materially and generating roughly $7.5M+ in proceeds across those trades. SEC Form 4 – Zojwalla sales
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at ~$30.46 (~$1.55M), trimming his holding by ~8.5%—another insider sale contributing to near‑term selling pressure. SEC Form 4 – Myles sale 12/19/2025

Institutional Trading of Olema Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in Olema Pharmaceuticals in the 3rd quarter worth $53,000. Ameritas Investment Partners Inc. boosted its stake in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after purchasing an additional 2,168 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after buying an additional 5,866 shares during the period. FNY Investment Advisers LLC raised its stake in Olema Pharmaceuticals by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after buying an additional 5,000 shares in the last quarter. Finally, Quarry LP bought a new position in Olema Pharmaceuticals in the first quarter worth about $45,000. Institutional investors own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

OLMA has been the topic of several analyst reports. HC Wainwright lifted their price objective on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. The Goldman Sachs Group upped their price target on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Guggenheim initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer boosted their price objective on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Finally, Citigroup upped their price objective on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $40.50.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.